Physician Publications

7/11/2017

Patient Case Lessons: Endocrine Management of Advanced Breast Cancer

Neelima Denduluri, M.D.

5/11/2017

Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer

Raymond Wadlow, M.D.

4/3/2017

American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations

Neelima Denduluri, M.D.

2/10/2017

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.

Neelima Denduluri, M.D.

2/6/2017

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Neelima Denduluri, M.D.

2/6/2017

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

Neelima Denduluri, M.D.

12/20/2016

Nondiscrimination and Accessibility Requirements Notice


7/29/2016

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

Anne M. Favret, M.D.

7/27/2016

Innovations in American Society of Clinical Oncology Practice Guideline Development.

Neelima Denduluri, M.D.

7/27/2016

Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary.

Neelima Denduluri, M.D.

7/27/2016

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Neelima Denduluri, M.D.

6/5/2016

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.


5/10/2016

Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.

Felasfa M. Wodajo, M.D.

5/3/2016

Challenges With Research Contract Negotiations in Community-Based Cancer Research.


3/22/2016

ReCAP: Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool.


3/9/2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Alex Spira, M.D., PhD, F.A.C.P.

3/1/2016

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.


2/15/2016

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Mitul Gandhi, M.D.

1/1/2016

Importance of pharmacokinetic studies in the management of acquired factor X deficiency

Timothy A. McCarthy, M.D.

11/1/2015

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Anne M. Favret, M.D.Neelima Denduluri, M.D.

10/1/2015

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

John Feigert, M.D.

9/14/2015

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Alex Spira, M.D., PhD, F.A.C.P.

9/1/2015

Are Complications Associated With the Repiphysis® Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use?

Felasfa M. Wodajo, M.D.

5/1/2015

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.


4/1/2015

Top Five Lesions That Do Not Need Referral to Orthopedic Oncology.

Felasfa M. Wodajo, M.D.

2/1/2015

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

Raymond Wadlow, M.D.

12/10/2014

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.


10/27/2014

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer


9/17/2014

What is the effect of advanced age and comorbidity on postoperative morbidity and mortality after musculoskeletal tumor surgery?

Felasfa M. Wodajo, M.D.

7/15/2014

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma

Raymond Wadlow, M.D.

7/14/2014

Angiogenesis Inhibitors in Gastric Cancer

Timothy A. McCarthy, M.D.

6/1/2014

A streamlined failure mode and effects analysis

Gregory S. Sibley, M.D.

5/20/2014

Coginitive Impairments in Older Breast Cancer Patients Prior to Systemic Therapy: Is There an Interaction between Cancer and Comorbidity

Neelima Denduluri, M.D.

5/14/2014

A Pilot Phase I/II Personalized Therapy Trial For Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping For Stratifying Patients To Therapy With Imatinib And Panitumumab

Alex Spira, M.D., PhD, F.A.C.P.

5/1/2014

Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse

Mitul Gandhi, M.D.

4/22/2014

Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.

Mitul Gandhi, M.D.

4/16/2014

Hemophagocytic lymphohistiocytosis and disseminated histoplasmosis

Alina M. Huang, M.D.

2/13/2014

Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.

Mitul Gandhi, M.D.

2/5/2014

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Raymond Wadlow, M.D.

1/16/2014

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Dipti Patel-Donnelly, M.D.

1/15/2014

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Alex Spira, M.D., PhD, F.A.C.P.

12/11/2013

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

Alex Spira, M.D., PhD, F.A.C.P.

12/1/2013

Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Neelima Denduluri, M.D.

11/15/2013

Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)

Mitul Gandhi, M.D.

10/10/2013

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

Jacob A. Ninan, M.D.

10/1/2013

Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial.

Alex Spira, M.D., PhD, F.A.C.P.

9/3/2013

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Anne M. Favret, M.D.

6/3/2013

Bridging to Survivorship in Breast Cancer-How BMI Weighs In?

Neelima Denduluri, M.D.

6/3/2013

Bridging to survivorship in breast cancer: learning how treatment impacts mental health among early stage breast cancer survivors.

Neelima Denduluri, M.D.

6/3/2013

A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer.


6/3/2013

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Alex Spira, M.D., PhD, F.A.C.P.

6/3/2013

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Raymond Wadlow, M.D.

6/2/2013

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

Dipti Patel-Donnelly, M.D.

6/2/2013

A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

Raymond Wadlow, M.D.

4/10/2013

Antiangiogenic therapies for advanced hepatocellular carcinoma

Keeran R. Sampat, M.D.

2/2/2013

Expert Insight: Lapatinib Tested as Adjuvant Therapy in HER2+ Breast Cancer

Neelima Denduluri, M.D.

2/2/2013

Expert Insight: Genomic Variants Used To Further Stratify Risk in Breast Cancer

Anne M. Favret, M.D.

2/1/2013

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Alex Spira, M.D., PhD, F.A.C.P.

2/1/2013

Pleural effusions in patients with acute leukemia and myelodysplastic syndrome

Keeran R. Sampat, M.D.

1/7/2013

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure

Mitul Gandhi, M.D.

1/2/2013

Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma

Alex Spira, M.D., PhD, F.A.C.P.

1/1/2013

Brentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma

Mitul Gandhi, M.D.

12/15/2012

Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study

Neelima Denduluri, M.D.

12/15/2012

A Structured Genetic Risk Evaluation and Testing Program in the Community Oncology Practice Increases Identification of Individuals at Risk for BRCA Mutations.

Neelima Denduluri, M.D.

12/15/2012

Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early Breast Cancer in the Community Setting.

Neelima Denduluri, M.D.

12/8/2012

A Phase 1/2 Study of Carlfilzomib as a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen.

Dipti Patel-Donnelly, M.D.

11/15/2012

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Dipti Patel-Donnelly, M.D.

9/13/2012

Risk of acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy for early breast cancer in the community setting.

Neelima Denduluri, M.D.

6/15/2012

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

Raymond Wadlow, M.D.

6/10/2012

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome.

John Feigert, M.D.

6/1/2012

Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2012

Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer

Neelima Denduluri, M.D.

4/16/2012

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Alex Spira, M.D., PhD, F.A.C.P.

4/13/2012

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzuma


3/14/2012

Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.


3/11/2012

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy

Raymond Wadlow, M.D.

3/1/2012

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.


1/1/2012

Clinical trial design in the age of molecular profiling.

Alex Spira, M.D., PhD, F.A.C.P.

12/30/2011

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

Raymond Wadlow, M.D.

12/11/2011

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Dipti Patel-Donnelly, M.D.

9/8/2011

Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)

Neelima Denduluri, M.D.

9/8/2011

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Ixabepilone: Clinical Role in Metastatic Breast Cancer

Neelima Denduluri, M.D.

6/1/2011

Phase II Study of Single-Agent Volasertib (BI 6727) for Second-Line Treatment of Urothelial Cancer (UC).

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study.

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Alex Spira, M.D., PhD, F.A.C.P.

6/1/2011

Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

Keeran R. Sampat, M.D.

4/11/2011

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial


3/7/2011

Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative Locally-Recurrent or Metastatic Breast Cancer


2/1/2011

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.


1/1/2011

Whole Gene Expression Profiling in Ankylosing Spondylitis Shows Upregulation of Toll-Like Receptor 4 and 5

Keeran R. Sampat, M.D.

12/28/2010

Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline-Based Chemotherapy


12/4/2010

Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.

Alex Spira, M.D., PhD, F.A.C.P.

12/1/2010

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.

Alex Spira, M.D., PhD, F.A.C.P.

12/1/2010

Estimate of current hospice and palliative medicine physician workforce shortage.

Loren Friedman, M.D., F.A.A.H.P.M.

8/1/2010

The role of targeted agents in preoperative chemoradiation for rectal cancer

Raymond Wadlow, M.D.

7/1/2010

Direct-to-consumer advertising by companies: not ready for prime time – and maybe never.

Patricia Rodriguez,  M.D.